Table 4:
Comparison of patients that never versus ever relapsed.
| Characteristics | Never relapse (n = 89) | Relapse (n = 114) | P-value |
|---|---|---|---|
| Presenting nephrotic event | |||
| Initial age (years), mean ± SD | 43 ± 17 | 41 ± 15 | .48 |
| Initial BMI, median (IQR) | 27 (24–32) | 27 (23–32) | .76 |
| eGFR (ml/min/1.73 m2), mean ± SD | 67 ± 30 | 70 ± 28 | .38 |
| Maximal proteinuria (g/day), median (IQR) | 6.9 (4.7–10.1) | 7.1 (5.1–11.6) | .16 |
| Nadir albumin (g/l), mean ± SD | 29 ± 10 | 28 ± 9 | .38 |
| Initial MAP (mmHg), mean ± SD | 106 ± 16 | 103 ± 14 | .16 |
| Initial number of BP medications, median (IQR) | 1 (0–2) | 1 (0–2) | .24 |
| Use of RAS blocker, % | 35 | 30 | .45 |
| Immunosuppressive treatment, % | 78 | 81 | .58 |
| Time to partial remission (months), median (IQR) | 10 (4–19) | 8 (4–20) | .74 |
| First remission period | |||
| Complete remission, % | 40 | 17 | <.001 |
| eGFR at start of remission (ml/min/1.73 m2), mean ± SD | 63 ± 31 | 66 ± 30 | .50 |
| Nadir proteinuria (g/day), median (IQR) | 0.5 (0.2–1.0) | 1.6 (0.7–2.5) | <.001 |
| Maximal albumin (g/l), mean ± SD | 43 ± 4 | 39 ± 5 | <.001 |
| MAP at start of remission (mmHg), mean ± SD | 95 ± 10 | 97 ± 12 | .19 |
| Number of BP medications at start of remission, median (IQR) | 1 (1–2) | 1 (0–2) | .83 |
| Use of RAS blocker at start of remission, % | 57 | 54 | .68 |